Field Safety Experience With an Autologous Cancer Vaccine in 41 Horses: A Retrospective Study (2019-2021).
Authors: Greenberg Chelsea B, Javsicas Laura H, Clauson Ryan M, Suckow Mark A, Kalinauskas Ashley E, Lucroy Michael D
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Autologous Cancer Vaccine Safety in Equine Patients Autologous cancer vaccines represent a promising immunotherapeutic approach for equine oncology, utilising the horse's own tumour cells to stimulate a targeted immune response against patient-specific cancer antigens. This retrospective analysis examined safety data from 41 horses that underwent biopsy or surgical resection followed by at least one subcutaneous injection of an adjuvanted whole-cell autologous vaccine (ACV-T), collectively receiving 252 doses over the 2019–2021 period. Adverse events proved remarkably rare, with only four horses experiencing mild reactions accounting for 1.6% of total administered doses, suggesting excellent tolerability compared to conventional adjuvant chemotherapy protocols. For practitioners managing equine patients with solid tumours—particularly where owners seek alternatives to systemic toxicity concerns—this data supports ACV-T as a viable complementary treatment option with a favourable safety profile. However, the study's retrospective design and lack of efficacy endpoints mean that prospective trials evaluating tumour response rates and long-term survival outcomes remain essential before firm clinical recommendations can be made.
Read the full abstract on PubMed
Practical Takeaways
- •ACV-T can be considered a low-risk adjuvant therapy option for horses with solid tumors, with minimal adverse event rates compared to other cancer treatments
- •Owners seeking treatment with fewer side effects than conventional adjuvant therapies may find ACV-T valuable as a patient-specific immunotherapy approach
- •Further clinical efficacy studies are needed before recommending ACV-T as first-line therapy, but safety profile supports continued investigation
Key Findings
- •41 horses received 252 total doses of autologous cancer vaccine with only 7 adverse events reported (1.6% of doses)
- •All reported adverse events were mild in severity and occurred in 4 of 41 horses (9.8%)
- •Autologous cancer vaccine appears well-tolerated as an adjuvant cancer treatment option in horses